The deal doesn’t cap the work at 5 drugs, but it’s a handy way to outline the upside. Gilead is committing $ 109 m to a drug discovery partnership with Discovery Bio , which has developed the Kidney Genome Atlas of genetics and clinical data regarding the kidney . Gilead has provided $ 50 m in upfront cash , along with $ 5 m for equity and $ 54 m to support research into diabetic kidney disease . Goldfinch CEO Tony Johnson said the start - up will consider launching an application once it is closer to proof of concept data for new drugs .
Gilead is committing $ 109 m to a drug discovery partnership with Discovery Bio , which has developed the Kidney Genome Atlas of genetics and clinical data regarding the kidney . Gilead has provided $ 50 m in upfront cash , along with $ 5 m for equity and $ 54 m to support research into diabetic kidney disease . Goldfinch CEO Tony Johnson said the start - up will consider launching an application once it is closer to proof of concept data for new drugs .